Les résultats de l’étude clinique de phase I de l’anticorps bifonctionnel PD-1/CTLA-4 Iparomlimab/Tuvonralimab de Qilu Pharma, publiés en ligne dans le Journal of Hematology & Oncology USA – Français USA – English APAC – English USA – español USA – Deutsch
Rising Market Demand for High-Throughput Screening Bolsters Growth
Cryogenic Vials Market size to grow by USD 66.16 million from 2022 to 2027, North America to account for 36% of the market growth
Leading Proxy Advisory Firm ISS Recommends Illumina Shareholders Vote “FOR” Eight of Illumina’s Highly Qualified Director Nominees
Feedback from 153 Executives Across 92 Organizations from 37 Countries
America’s Best Wings: Everything You Need to Know
Oral sex at the origin of an “epidemic” of throat cancer?
When the tiger mosquito is in the crosshairs
APF-France handicap on a new territory
Cauvaldor still active in welcoming doctors
R. Saddiki: a new surgeon with new techniques for the hospital
Temporibus autem quibusdam et aut officiis debitis aut rerum necessitatibus saepe eveniet ut et voluptates.
